Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix GenoSphere™ Launches MASH-Enriched Cohort of Over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and DevelopmentOctober 15, 2025
Press ReleasesHelix to Present New Population-Scale Genomic Research at ASHG 2025 Annual MeetingOctober 7, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
Blog From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.By James Lu, MD, PhD, CEO and Co-Founder of Helix
Press ReleasesHelix GenoSphere™ Launches MASH-Enriched Cohort of Over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and DevelopmentOctober 15, 2025
Press ReleasesHelix to Present New Population-Scale Genomic Research at ASHG 2025 Annual MeetingOctober 7, 2025
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchFrom Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World EvidenceAugust 15, 2025
2Published ResearchNovel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse CohortJuly 30, 2025
3Published ResearchChatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering ProjectJune 10, 2025
4Published ResearchIndividuals with PMS2 pathogenic variants are at average risk of cancer before age 60March 19, 2025
5Published ResearchScalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptionsMarch 19, 2025
ResearchOct 19, 2022Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombinationCellpress
NewsOct 14, 2022New Omicron Covid-19 Subvariants on the Rise in U.S., CDC SaysThe Wall Street Journal
ResearchOct 8, 2022Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced MyocarditisSpringer
NewsOct 7, 2022CDC: Omicron Subvariants BA.4.6, BF.7 Increasing While BA.5 DeclinesUS News & World Report
Blog Oct 4, 2022Innovation in practice: using genomic testing in routine care to boost population health